Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067890 | PMC |
http://dx.doi.org/10.3389/fbioe.2023.1165782 | DOI Listing |
Front Chem
March 2024
Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Bologna, Italy.
Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer still lacking effective treatment options. Chemotherapy in combination with immunotherapy can restrict tumor progression and repolarize the tumor microenvironment towards an anti-tumor milieu, improving clinical outcome in TNBC patients. The chemotherapeutic drug paclitaxel has been shown to induce immunogenic cell death (ICD), whereas inhibitors of the indoleamine 2,3- dioxygenase 1 (IDO1) enzyme, whose expression is shared in immune regulatory and tumor cells, have been revealed to enhance the anti-tumor immune response.
View Article and Find Full Text PDFFront Bioeng Biotechnol
March 2023
Department of Pharmacology, Institute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University, Beijing, China.
Nanomedicine (Lond)
August 2021
Department of Pharmaceutics, College of Pharmacy, Third Military Medical University (Army Medical University), Chongqing, 400038, PR China.
Nanomedicine (Lond)
August 2020
Department of Pharmaceutics, College of Pharmacy, Third Military Medical University (Army Medical University), Chongqing, 400038, PR China.
Future Oncol
December 2019
Department of Chemistry, RCSI, 123 St. Stephen's Green, Dublin 2, Ireland.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!